PHAXIAM Therapeutics S.A.
PHXM · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $10,474 | – | $25,189 | $38,789 |
| Short-Term Investments | $0 | – | $0 | $43 |
| Receivables | $4,864 | – | $4,099 | $2,576 |
| Inventory | $0 | – | $1,633 | $1,268 |
| Other Curr. Assets | $881 | – | $1 | -$42 |
| Total Curr. Assets | $16,219 | – | $30,922 | $42,634 |
| Property Plant & Equip (Net) | $3,899 | – | $3,797 | $2,977 |
| Goodwill | $9,622 | – | $13,503 | $0 |
| Intangibles | $0 | – | $17,101 | $5 |
| Long-Term Investments | $0 | – | $0 | $0 |
| Tax Assets | $0 | – | $0 | $0 |
| Other NC Assets | $21,567 | – | $208 | $195 |
| Total NC Assets | $35,088 | – | $34,609 | $3,177 |
| Other Assets | $0 | – | $0 | $0 |
| Total Assets | $51,307 | – | $65,531 | $45,811 |
| Liabilities | – | – | – | – |
| Payables | $3,679 | – | $4,336 | $1,562 |
| Short-Term Debt | $3,887 | – | $828 | $3,340 |
| Tax Payable | $0 | – | $3,554 | $0 |
| Deferred Revenue | $0 | – | $420 | $51 |
| Other Curr. Liab. | $7,698 | – | $8,252 | $6,725 |
| Total Curr. Liab. | $15,264 | – | $17,390 | $11,678 |
| LT Debt | $7,030 | – | $2,559 | $10,227 |
| Deferred Rev, NC | $0 | – | $0 | $0 |
| Deferred Tax Liab, NC | $0 | – | $0 | $0 |
| Other NC Liab. | $3,401 | – | $8,950 | $420 |
| Total NC Liab. | $10,431 | – | $11,509 | $10,647 |
| Other Liabilities | $0 | – | $0 | $0 |
| Cap. Leases | $0 | – | $0 | $0 |
| Total Liabilities | $25,695 | – | $28,899 | $22,325 |
| Equity | – | – | – | – |
| Pref Stock | $0 | – | $0 | $0 |
| Common Stock | $6,075 | – | $6,075 | $3,102 |
| Retained Earnings | $0 | – | -$12,201 | -$228 |
| AOCI | -$30,134 | – | -$6,913 | -$28,363 |
| Other Equity | $49,671 | – | $49,671 | $48,975 |
| Total Equity | $25,612 | – | $36,632 | $23,486 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | – | $0 | $0 |
| Total Liab. & Tot. Equity | $51,307 | – | $65,531 | $45,811 |
| Net Debt | $443 | $0 | -$21,802 | -$25,222 |